Compare Coupang Inc (CPNG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Twist Bioscience Corp — how do they compare? Coupang Inc trades at $15.79 (market cap $27.70B), while Twist Bioscience Corp trades at $160.15 (market cap $10.08B). The key difference: Coupang Inc is far larger — about 2.7× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Twist Bioscience Corp for 27 Days on average.
| CPNG | TWST | |
|---|---|---|
Market Cap | $27.70B | $10.08B |
Volume | 27,703,608 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $205.00 |
52-Week Low | $13.75 | $25.45 |
Typical Hold Time | 55 Days | 27 Days |
Enterprise Value | $27.22B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPNG trades at $15.83, up 6.89% over 24 hours, with a bullish technical signal from moving averages and ADX. The company reported $34.53B revenue in 2025 with a net income of $208M, though recent quarters show earnings misses. Analyst consensus is strongly bullish with a $25.25 price target, and cash flow from operations remains positive at $1.77B.
The outlook is mixed: strong revenue growth and analyst support offer upside, but negative net income margin and high P/E of 184.18 signal overvaluation risks. Key risks include competitive pressure from MercadoLibre and Alibaba, and a projected net loss of $767M in 2026. Institutional sentiment is positive, but earnings volatility requires caution.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
